Clinical trialNCT05633602Active, not recruitingPhase 3Interventional

Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung Study

SponsorSWOG Cancer Research NetworkEnrollment838Recurrent Lung Non-Small Cell CarcinomaStage IV Lung Cancer AJCC v8

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This phase III trial compares the effect of the combination of ramucirumab and pembrolizumab versus standard of care chemotherapy for the treatment of non-small cell lung cancer that is stage IV or that has come back after a period of improvement (recurrent). Ramucirumab is a monoclonal antibody that may prevent the growth of new blood vessels that tumors need to grow. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial may help doctors find out if giving ramucirumab with pembrolizumab is more effective at treating patients with stage IV or recurrent non-small cell lung cancer than standard chemotherapy.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

Karen L Reckamp
SWOG Cancer Research Network
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

566 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

University of Alabama at Birmingham Cancer Center
Birmingham, Alabama, United States
University of South Alabama Mitchell Cancer Institute
Mobile, Alabama, United States
Banner University Medical Center - Tucson
Tucson, Arizona, United States
University of Arizona Cancer Center-North Campus
Tucson, Arizona, United States
Highlands Oncology Group - Fayetteville
Fayetteville, Arkansas, United States
Mercy Hospital Fort Smith
Fort Smith, Arkansas, United States
John L Mcclellan Memorial Veterans Hospital
Little Rock, Arkansas, United States
University of Arkansas for Medical Sciences
Little Rock, Arkansas, United States
Highlands Oncology Group - Rogers
Rogers, Arkansas, United States
Highlands Oncology Group
Springdale, Arkansas, United States
Kaiser Permanente-Anaheim
Anaheim, California, United States
Pcr Oncology
Arroyo Grande, California, United States
Sutter Auburn Faith Hospital
Auburn, California, United States
Kaiser Permanente-Baldwin Park
Baldwin Park, California, United States
Kaiser Permanente-Bellflower
Bellflower, California, United States
Alta Bates Summit Medical Center-Herrick Campus
Berkeley, California, United States
Tower Cancer Research Foundation
Beverly Hills, California, United States
Marshall Cancer Center
Cameron Park, California, United States
City of Hope Comprehensive Cancer Center
Duarte, California, United States
Kaiser Permanente Dublin
Dublin, California, United States
Kaiser Permanente-Fontana
Fontana, California, United States
Kaiser Permanente-Fremont
Fremont, California, United States
Palo Alto Medical Foundation-Fremont
Fremont, California, United States
Kaiser Permanente - Harbor City
Harbor City, California, United States
City of Hope at Huntington Beach
Huntington Beach, California, United States
City of Hope at Irvine Lennar
Irvine, California, United States
Kaiser Permanente-Irvine
Irvine, California, United States
City of Hope Antelope Valley
Lancaster, California, United States
Loma Linda University Medical Center
Loma Linda, California, United States
City of Hope at Long Beach Elm
Long Beach, California, United States
Cedars Sinai Medical Center
Los Angeles, California, United States
Kaiser Permanente Los Angeles Medical Center
Los Angeles, California, United States
Kaiser Permanente West Los Angeles
Los Angeles, California, United States
Fremont - Rideout Cancer Center
Marysville, California, United States
Kaiser Permanente-Modesto
Modesto, California, United States
Memorial Medical Center
Modesto, California, United States
City of Hope Newport Beach
Newport Beach, California, United States
Kaiser Permanente-Oakland
Oakland, California, United States
Kaiser Permanente-Ontario
Ontario, California, United States
Palo Alto Medical Foundation Health Care
Palo Alto, California, United States

526 more sites on the registry record.ClinicalTrials.gov ↗

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Chemotherapy →Pembrolizumab →Ramucirumab →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 14 Mar 2023
Primary completion: 26 Nov 2025
Completion: 15 Mar 2028
Last update posted: 17 Apr 2026
Registered enrollment: 838
Registry id: NCT05633602

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.